Business · 27/01/2000Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for GlucaGen Patent Extension
Summary
The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for GlucaGen, a human drug product, in response to a patent extension application submitted to the US Department of Commerce
Original source language: Federal Register — Food and Drug AdministrationOpen original release →